BIAF Stock Rockets As CyPath Lung Growth Collides With Delisting Risk

bioAffinity Technologies Inc. stocks have been trading up by 30.15 percent following highly promising diagnostic trial results.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

CyPath Lung test volume jumped 216% year over year, with physician accounts up 122% and existing customer orders up 71%, driving a 159% first‑half revenue surge to about $0.8M.
Q2 2026 EPS narrowed to -$0.64 from -$5.07 on revenue of $1.5M versus $1.27M, showing better operating leverage even as BIAF remains deeply unprofitable.
A nationwide AvMEDICAL deal opens CyPath Lung to VA and other federal systems through established government sales channels and IDIQ contracting.
BIAF is pushing CyPath Lung into post‑treatment surveillance and running a VA‑ and military‑backed longitudinal trial, while extending its pipeline into asthma/COPD diagnostics and topical siRNA skin cancer therapeutics.
Cash sat near $2.4M at 2026/06/30, partly offset by a $3.2M equity raise, and BIAF faces Nasdaq delisting risk, signaling ongoing dilution and high execution risk.

Live Update At 07:47:22 EDT: On Thursday, September 03, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 30.15%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, BIAF is a classic small-cap biotech rollercoaster. The business is showing real traction, but the P&L is still bleeding red. In Q2 2026, bioAffinity Technologies Inc. delivered revenue of $1.5M, up from $1.27M a year earlier. That 19% growth is modest on its own, yet it sits on top of a much faster ramp inside CyPath Lung, where first‑half sales climbed about 159% to roughly $0.8M.

EPS improved to -$0.64 from a brutal -$5.07. That reflects both operating leverage and a larger share count after capital raises. BIAF still posted about -$3.4M in quarterly net loss and free cash flow near -$3.3M, so the path to break‑even remains long.

On the balance sheet, BIAF reported about $2.4M of cash at 2026/06/30, with operating cash burn above $3.2M for the quarter and fresh equity bringing in about $2.7M. Ratios underline the story: price‑to‑sales around 0.67 looks cheap on paper, but returns on equity and assets are deeply negative. For traders, that combination usually means binary sentiment swings driven by news and liquidity.

More Breaking News

The chart confirms that. BIAF traded under $0.50 in mid‑August, then exploded to $9.75 by 2026/09/02, with intraday spikes above $14. This is momentum‑trader territory—huge range, thin float behavior, and crowded day‑trading action.

Why Traders Are Watching BIAF Right Now

BIAF has become a tape you cannot ignore if you hunt volatility. The core driver is CyPath Lung, the company’s noninvasive sputum‑based lung cancer diagnostic. Operationally, bioAffinity Technologies Inc. is finally getting the kind of traction traders like to see: CyPath Lung test volume up 216%, physician accounts up 122%, and existing customer orders up 71%. That kind of growth tends to pull in momentum algos and breakout traders.

The story doesn’t stop there. BIAF also signed a nationwide distribution agreement with AvMEDICAL, plugging CyPath Lung into VA and broader federal healthcare systems. For a micro‑cap, landing access to the Department of Veterans Affairs and other federal buyers through an existing government‑focused sales force is a big credibility signal. Traders know that even if revenue from this channel phases in slowly, the headline alone can sustain buzz and volume.

At the same time, BIAF is stretching CyPath Lung beyond early detection into surveillance of lung cancer survivors. That opens a recurring‑use market where patients are monitored for recurrence and new primary cancers, potentially increasing revenue per patient over time. Add in a VA‑ and military‑backed longitudinal trial plus early‑stage work in asthma/COPD diagnostics and topical siRNA skin cancer therapeutics, and you get a broader platform narrative, not just a single‑product story.

The result on the screen is obvious. BIAF went from sub‑$1 to nearly $12 in a couple of weeks, and intraday 5‑minute candles show repeated pushes into the $13–$14 range before sharp pullbacks. This is classic high‑beta biotech behavior—news‑driven legs higher, then violent mean reversion when profit‑taking hits.

Conclusion

For traders, BIAF sits at the crossroads of real business progress and serious financial strain. On one hand, bioAffinity Technologies Inc. is delivering what growth‑focused traders want to see: surging CyPath Lung adoption, expanding physician coverage, recurring order strength, and a new federal distribution deal via AvMEDICAL. The expansion into post‑treatment surveillance and the broader pipeline give BIAF a longer runway of potential catalysts.

On the other hand, the numbers under the hood stay harsh. BIAF is still losing more than $3M a quarter, burning cash faster than it brings it in, and relying on equity raises to stay afloat. Nasdaq delisting risk hangs over the ticker, pointing toward continued dilution and possible volatility around any compliance announcements. For short‑term trading, that mix of momentum and structural risk is exactly what fuels big intraday swings.

This is why BIAF demands a disciplined game plan. As Tim Sykes loves to repeat, “The market doesn’t care about your opinion, only your preparation and your rules.” As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” For BIAF, that means mapping key levels from the recent run, respecting liquidity shifts around headlines, and cutting losses fast if the breakout fails. This article is for educational and research purposes only, but the lesson is clear: BIAF is a powerful trading vehicle right now—but only for traders who treat the chart, the news, and their risk rules with equal respect.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!